Moderna recently provided an update on its phase 3 trial investigating the mRNA-1403 vaccine candidate for norovirus. The trial, called Nova 301, aims to assess the safety, efficacy, and immunogenicity of the vaccine designed to protect against multiple norovirus genotypes. Enrolment is expected to reach about 25,000 participants, including 20,000 individuals aged 60 and older. Study participants will be randomly assigned to receive either mRNA-1403 or a placebo intramuscular injection. Efficacy data may be available in early 2025 if the first season shows sufficient cases of norovirus. If not, the study could expand to a second season.
The highly contagious norovirus can spread through direct contact, contaminated food, or drink and is a leading cause of diarrheal disease and foodborne illness in the U.S., particularly affecting young children, older adults, and immunocompromised individuals. Recent data from the CDC show an increase in norovirus cases this winter.
This article originally appeared on MPR.
Source: https://www.pulmonologyadvisor.com/news/moderna-provides-update-on-norovirus-vaccine-candidate